The ET options for ER+ primary breast cancer include aromatase inhibitors that block the conversion of androgen to estrogen, or selective estrogen receptor modulators that antagonize ER activation by reducing co-factor binding [2]. The gene discussed is ESR1; the disease is breast cancer.